Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
University of Twente, Faculty TNW, The Netherlands.
Br J Surg. 2021 Dec 17;109(1):53-60. doi: 10.1093/bjs/znab339.
There is a transition from wire-guided localization (WGL) of non-palpable breast cancer to other localization techniques. Multiple prospective studies have sought to establish superior clinical outcomes for radioactive-seed localization (RSL), but consistent and congruent evidence is missing.
In this study, female patients with breast cancer operated with breast-conserving surgery after tumour localization of a non-palpable breast cancer or ductal carcinoma in situ (DCIS) were included. The cohort was identified from the nationwide Netherlands Breast Cancer Audit conducted between 2013 and 2018. Trends in localization techniques were analysed. Univariable and multivariable analyses were performed to assess the association between the localization technique and the probability of a reoperation.
A total of 28 370 patients were included in the study cohort. The use of RSL increased from 15.7 to 61.1 per cent during the study years, while WGL decreased from 75.4 to 31.6 per cent. The localization technique used (RSL versus WGL) was not significantly associated with the odds of a reoperation, regardless of whether the lesion was DCIS (odds ratio 0.96 (95 per cent c.i. 0.89 to 1.03; P = 0.281)) or invasive breast cancer (OR 1.02 (95 per cent c.i. 0.96 to 1.10; P = 0.518)).
RSL is rapidly replacing WGL as the preoperative localization technique in breast surgery. This large nationwide registry study found no association between the type of localization technique and the odds of having a reoperation, thus confirming the results of previous prospective cohort studies.
从导丝引导定位(WGL)到其他定位技术,非可触及乳腺癌的定位方法正在发生转变。多项前瞻性研究试图确定放射性种子定位(RSL)在临床结果上的优越性,但始终缺乏一致性和一致性的证据。
本研究纳入了在 2013 年至 2018 年期间进行肿瘤定位后接受保乳手术的女性乳腺癌患者。该队列是从全国性荷兰乳腺癌审计中确定的。分析了定位技术的趋势。进行单变量和多变量分析,以评估定位技术与再次手术概率之间的关联。
共纳入 28370 例患者。RSL 的使用率从研究期间的 15.7%上升到 61.1%,而 WGL 的使用率从 75.4%下降到 31.6%。使用的定位技术(RSL 与 WGL)与再次手术的几率无关,无论病变是 DCIS(比值比 0.96(95%置信区间 0.89 至 1.03;P=0.281))还是浸润性乳腺癌(OR 1.02(95%置信区间 0.96 至 1.10;P=0.518))。
RSL 正在迅速取代 WGL,成为乳房手术的术前定位技术。这项大型全国性注册研究发现,定位技术类型与再次手术的几率之间没有关联,从而证实了先前前瞻性队列研究的结果。